Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Prelude Therapeutics Inc
(NQ:
PRLD
)
5.200
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Prelude Therapeutics Inc
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
October 14, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
August 29, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
May 31, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Pricing of Public Offering
May 18, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
May 17, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
May 08, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
March 15, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
March 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.